Neurotoxin is widely used as a therapeutic substance or an agent to treat various conditions. It is widely used for facial aesthetic and treating muscular movements and others. The internalization and cytosolic delivery of proteolytic enzymes property of neurotoxin that helps in slicing proteins integral to the exocytosis of neurotransmitters allow in treating medical conditions.
Market leaders operating in the market have undertaken various organic growth strategies in the neurotoxin market. the neurotoxin market majorly consists of the players Merz Pharma GmbH & Co KGaA, AbbVie Inc, Revance Therapeutics Inc, Ipsen SA, List Biological Labs Inc, Medytox Inc, Evolus Inc, Hugel Inc, Lanzhou Institute of Biological Products Co Ltd, Supernus Pharmaceuticals, and Guficare. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals.
Below is the list of inorganic growth strategies done by the players operating in the neurotoxin market:
|
Date |
Development |
Category |
Description |
|
Feb-2022 |
Merz strengthens partnership with start-up Vensica and invests up to $3 million. |
Partnership |
Merz Therapeutics is expanding its strategic partnership with Vensica Therapeutics as the Merz Group invests up to $3 million in the Israeli start-up. This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN) for the innovative ultrasound-assisted delivery catheter of Vensica. Merz is thus executing its contractually agreed option to participate in Vensica’s Series C financing round and invest further in the start-up. |
|
Aug-2021 |
Merz and Israeli start-up Vensica launch partnership for needleless treatment of overactive bladder |
Partnership |
Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN)to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications. |
|
Aug-2021 |
XEOMIN (incobotulinumtoxinA) receives european approval for the treatment of chronic sialorrhea in children |
Product Approval |
Merz Therapeutics has been granted the use of XEOMIN for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ? 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level. The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration approved in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021. XEOMIN is first and only botulinum neurotoxin approved for this indication in Europe. |
|
Jun-2020 |
Teijin receives marketing approval for Merz’s XEOMIN Botulinum Toxin Type A in Japan |
Product Approval |
Merz Therapeutics GmbH and Teijin Pharma Limited jointly announced that Teijin Pharma had been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market XEOMIN (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. XEOMIN is effective in treating peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine. |
Source: Press Release, Newsletters, and Company Annual Report
